In this issue:
- PD-1 blockade rechallenge in advanced NSCLC
- Outcomes after completing 2 years of pembrolizumab
- KRAS inhibition for treatment of NSCLC
- Future burden of lung cancer in NZ
- Review of MDM discussion on lung cancer outcomes
- Anlotinib with/without PD-1/ PD-L1 inhibitor in NSCLC
- Māori perspectives on:
– A national lung cancer screening programme
– Use of blood biomarkers in lung cancer screening
- Resection of NSCLC:
– VATS vs open surgery
– VATS vs RATS post neoadjuvant therapy
Please login below to download this issue (PDF)